Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly? [4]

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 538-539

  Todeschini, Guiseppe ^a   Gelio, S ^b   Tecchino, Cristina ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; GERIATRIC PATIENT; HUMAN; INFECTION; LETTER; LYMPHOMA; PRIORITY JOURNAL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 1842607577     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh112     Document Type: Letter

References (2)

1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. Pfreundschuh M, Trumper I, Kloess M et al. Two-weekly CHOP: the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 2002; 13 (Suppl 2): 27.